SONA Asset Management (US)’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

SONA Asset Management (US)’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90,898	Closed	-$3.73K	–	155
2023 Q1	$3.73K	Hold	90,898	–	–	﹤0.01%	102
2022 Q4	$4.54K	Hold	90,898	–	–	﹤0.01%	167
2022 Q3	$5K	Hold	90,898	–	–	﹤0.01%	209
2022 Q2	$8K	Hold	90,898	–	–	0.01%	207
2022 Q1	$897K	Hold	90,898	–	–	0.51%	57
2021 Q4	$45K	Buy	+90,898	New	+$51.3K	0.02%	205

Other funds holding CLDI.WS

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

SONA Asset Management (US)'s CLDI.WS Position: Q2 2023 in Review

SONA Asset Management (US) sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q2 2023, closing a stake of 90,898 shares — an estimated $3.73K sold.

SONA Asset Management (US) first reported a position in CLDI.WS in Q4 2021 and held it in 6 quarters. The position peaked at $897K in Q1 2022. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q2 2023.

SONA Asset Management (US) reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q2 2023 after selling out during the quarter.
SONA Asset Management (US) sold 90,898 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q2 2023, an estimated $3.73K.
SONA Asset Management (US) first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 6 quarters.
SONA Asset Management (US)'s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $897K in Q1 2022.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q2 2023.

Based on SONA Asset Management (US)'s 13F filing for Q2 2023, filed 11 Aug 2023.